Literature DB >> 17386984

Androgens and the breast.

Bo von Schoultz1.   

Abstract

There is increasing interest in the role of androgens in the treatment of women but little is known about their long-term safety. There are also very few studies on testosterone therapy and breast cancer risk. However, some observations support the concept that androgens may counteract the stimulatory effects of estrogen and progestogen in the mammary gland. Mammographic breast density and breast cell proliferation could be regarded as surrogate markers for the risk of breast cancer. Recently the addition of testosterone to a common estrogen/progestogen regimen was found to inhibit the stimulatory effects of hormones on breast cell proliferation. The effects of testosterone alone on the postmenopausal breast remain to be investigated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17386984     DOI: 10.1016/j.maturitas.2007.02.012

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  6 in total

1.  Immunocytochemical localization of sex steroid hormone receptors in normal human mammary gland.

Authors:  Sijie Li; Bing Han; Guojin Liu; Songyun Li; Johanne Ouellet; Fernand Labrie; Georges Pelletier
Journal:  J Histochem Cytochem       Date:  2009-12-21       Impact factor: 2.479

2.  17beta-hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production.

Authors:  Juliette A Aka; Mausumi Mazumdar; Chang-Qing Chen; Donald Poirier; Sheng-Xiang Lin
Journal:  Mol Endocrinol       Date:  2010-02-19

3.  Mammary gland and endometrial effects of testosterone in combination with oral estradiol and progesterone.

Authors:  Charles E Wood; Cynthia J Lees; J Mark Cline
Journal:  Menopause       Date:  2009 May-Jun       Impact factor: 2.953

4.  Bioanalytical LC-MS Method for the Quantification of Plasma Androgens and Androgen Glucuronides in Breast Cancer.

Authors:  Eleni Kalogera; Constantinos Pistos; Xeni Provatopoulou; Costas A Christophi; George C Zografos; Maria Stefanidou; Chara Spiliopoulou; Sotirios Athanaselis; Antonia Gounaris
Journal:  J Chromatogr Sci       Date:  2016-01-12       Impact factor: 1.618

5.  Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy.

Authors:  C Derzko; S Elliott; W Lam
Journal:  Curr Oncol       Date:  2007-12       Impact factor: 3.677

Review 6.  Benefits and risks of testosterone treatment for hypoactive sexual desire disorder in women: a critical review of studies published in the decades preceding and succeeding the advent of phosphodiesterase type 5 inhibitors.

Authors:  Sandra Léa Bonfim Reis; Carmita H N Abdo
Journal:  Clinics (Sao Paulo)       Date:  2014       Impact factor: 2.365

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.